Sandra Herranz

Pharmacological Therapies Unit,
Research Institute for Rare Diseases,
Pharmacological Therapies Unit, Research Institute for Rare Diseases

Institute of Health Carlos III

BIOGRAPHY

Sandra Herranz has not added Biography.

If you are Sandra Herranz and would like to personalize this page please email our Author Liaison for assistance.

PUBLICATIONS

Tumor suppressor ARF regulates tissue microenvironment and tumor growth through modulation of macrophage polarization.

Oncotarget Oct, 2016 | Pubmed ID: 27572316

Practical utility of on-line clearance and blood temperature monitors as noninvasive techniques to measure hemodialysis blood access flow.

Blood purification , 2011 | Pubmed ID: 21135543

Labdanolic acid methyl ester (LAME) exerts anti-inflammatory effects through inhibition of TAK-1 activation.

Toxicology and applied pharmacology Jan, 2012 | Pubmed ID: 22036724

Metabolic control and treatment patterns in patients with type 1 diabetes in Castilla-La Mancha: the DIAbetes tipo 1 in Castilla La Mancha study.

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion Nov, 2012 | Pubmed ID: 23039989

Role of the tumor suppressor ARF in macrophage polarization: Enhancement of the M2 phenotype in ARF-deficient mice.

Oncoimmunology Nov, 2012 | Pubmed ID: 23243586

Demographic, clinical, and genetic characteristics of patients with medullary thyroid cancer in the past 16 years in Castilla-La Mancha.

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion Oct, 2014 | Pubmed ID: 24794695

Critical role of p38 MAPK in IL-4-induced alternative activation of peritoneal macrophages.

European journal of immunology Jan, 2015 | Pubmed ID: 25328047

α-Hispanolol sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis via death receptor up-regulation.

Toxicology and applied pharmacology Aug, 2015 | Pubmed ID: 25930665

8,9-Dehydrohispanolone-15,16-lactol diterpene prevents LPS-triggered inflammatory responses by inhibiting endothelial activation.

The Biochemical journal Jul, 2016 | Pubmed ID: 27154204

INSTITUTIONS

Institute of Health Carlos III

JOVE ARTICLES

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

María Ángeles Higueras¹,

Lidia Jiménez-García¹,

Sandra Herranz¹,

Sonsoles Hortelano^*,1,

Alfonso Luque^*,1

¹Pharmacological Therapies Unit, Research Institute for Rare Diseases, Institute of Health Carlos III

Immunology and Infection

Privacy

Policies

Recommend to library

JoVE NEWSLETTERS

Research

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

Education

JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Playlist
Faculty Site

Authors

Overview
Publishing Process
Editorial Board
Scope and Policies
Peer Review
FAQ
Submit

Librarians

Overview
Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center
JoVE Sitemap

We use cookies to enhance your experience on our website.

By continuing to use our website or clicking “Continue”, you are agreeing to accept our cookies.

Learn More

Sandra Herranz

Pharmacological Therapies Unit,Research Institute for Rare Diseases,Pharmacological Therapies Unit, Research Institute for Rare Diseases

Institute of Health Carlos III

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Pharmacological Therapies Unit,
Research Institute for Rare Diseases,
Pharmacological Therapies Unit, Research Institute for Rare Diseases